Trex Medical Corporation Launches ‘Vision of Health Initiative’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 12
Volume 8
Issue 12

DANBURY, Conn-Trex Medical Corporation has announced the launch of its Vision of Health Initiative, a new philanthropic program that will commit up to $100,000 a year to health education, research, and patient support programs across the country. Trex Medical has chosen the National Alliance of Breast Cancer Organizations (NABCO) as the first grant recipient. NABCO is a nonprofit organization providing information and resources on breast cancer.

DANBURY, Conn—Trex Medical Corporation has announced the launch of its Vision of Health Initiative, a new philanthropic program that will commit up to $100,000 a year to health education, research, and patient support programs across the country. Trex Medical has chosen the National Alliance of Breast Cancer Organizations (NABCO) as the first grant recipient. NABCO is a nonprofit organization providing information and resources on breast cancer.

Vision of Health Initiative funds will support NABCO’s innovative efforts to deliver the mammography message to women, their families, medical professionals, and the media. Trex will make a donation to NABCO for each mammography and breast biopsy unit it sells between January and December 2000.

The first program the initiative will support is NABCO’s E-Mail Reminder campaign that prompts women to schedule regular screening mammograms and breast exams. The program invites women to register to be reminded by an e-mail message from NABCO that their exam anniversary is approaching. They can also print out individualized breast health information at the site.

NABCO anticipates that the grant will also help fund a corporate website program through which employers can offer workplace e-mail sign-ups to their female employees using the NABCO E-Mail Reminder icon on the company’s internal site. Currently, women can sign up for the free e-mail reminder program by visiting www.nabco.org.

“This contribution by Trex Medical Corporation celebrates the good news about early detection,” said Amy Langer, NABCO’s executive director and a cancer survivor. “Finding breast cancer early offers the best chance to treat it effectively. This important support will let us help even more women take charge of their breast health.”

Trex Medical Corporation is a leading manufacturer of mammography equipment and minimally invasive digital breast biopsy systems, as well as a manufacturer of digital dental x-ray equipment. To find out more about the Trex Medical initiative, please visit the company’s website at www.trexmedical.com.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content